ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Tempest Therpeutics Inc

Tempest Therpeutics Inc (TPST)

3.18
-0.04
(-1.24%)
Closed May 19 4:00PM
3.2888
0.1088
(3.42%)
After Hours: 7:42PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
3.2888
Bid
3.20
Ask
3.29
Volume
317,970
3.12 Day's Range 3.26
0.17 52 Week Range 9.77
Market Cap
Previous Close
3.22
Open
3.21
Last Trade
1
@
3.24
Last Trade Time
Financial Volume
$ 1,017,050
VWAP
3.1986
Average Volume (3m)
896,391
Shares Outstanding
19,247,495
Dividend Yield
-
PE Ratio
-2.07
Earnings Per Share (EPS)
-1.53
Revenue
-
Net Profit
-29.49M

About Tempest Therpeutics Inc

Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Tempest Therpeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TPST. The last closing price for Tempest Therpeutics was $3.22. Over the last year, Tempest Therpeutics shares have traded in a share price range of $ 0.17 to $ 9.77.

Tempest Therpeutics currently has 19,247,495 shares outstanding. The market capitalization of Tempest Therpeutics is $61.01 million. Tempest Therpeutics has a price to earnings ratio (PE ratio) of -2.07.

TPST Latest News

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for TPST-1120 in kidney cancer at the AACR Annual...

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...

Tempest Reports New Preclinical Data for TPST-1120Β in RCC at the AACR Annual Meeting

BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized...

Tempest Reports Year End 2023 Financial Results andΒ Provides Business Update

Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in...

Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types

BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2512-7.096045197743.543.58393.123696543.3113193CS
40.12884.075949367093.163.793.06113510183.42893619CS
12-0.4212-11.35309973053.7163.038963914.34776121CS
260.02880.8834355828223.2662.8810108184.12376266CS
521.198857.35885167462.099.770.1731501115.85755695CS
156-10.5212-76.185372918213.81410.1712033186.38743068CS
260-10.5212-76.185372918213.81410.1712033186.38743068CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DUOFangDD Network Group Ltd
$ 1.65
(313.74%)
104.68M
FLJFLJ Group Limited
$ 1.54
(220.90%)
57.28M
JFBRJeffs Brands Ltd
$ 0.6276
(102.45%)
37.97M
IPWiPower Inc
$ 2.89
(97.95%)
11.05M
CETXCemtrex Inc
$ 0.4851
(48.58%)
21.23M
BSFCBlue Star Foods Corporation
$ 0.0757
(-45.26%)
60.09M
SINTSiNtx Technologies Inc
$ 0.084602
(-39.57%)
156.35M
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
HSCSHeart Test Laboratories Inc
$ 7.00
(-38.11%)
348.9k
AMPGAmplitech Group Inc
$ 1.46
(-32.09%)
613.31k
CRKNCrown Electrokinetics Corporation
$ 0.171
(-28.75%)
1.74B
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
GWAVGreenwave Technology Solutions Inc
$ 0.1541
(4.05%)
1.16B
AKANAkanda Corporation
$ 0.1726
(30.26%)
566.51M
PEGYPineapple Energy Inc
$ 0.1053
(-28.85%)
219.25M

TPST Discussion

View Posts
rouge Vaughn rouge Vaughn 2 months ago
yup and time to go up even more let's pass 7 and up trmw
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 months ago
UPstink today
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
TPST under $4
πŸ‘οΈ0
retireat40 retireat40 5 months ago
El stinko day today
πŸ‘οΈ0
BurgerKing82 BurgerKing82 5 months ago
Any other bio cheapies besides hook
πŸ‘οΈ0
Triple nickle Triple nickle 5 months ago
Was that you 3.12 big
πŸ‘οΈ0
ORCA ORCA 5 months ago
OUT AT 3.53:))))
πŸ‘οΈ0
ORCA ORCA 5 months ago
$3.43:))))
πŸ‘οΈ0
ORCA ORCA 5 months ago
FROM 2.92 MY CALL.NOW 3.38:))))
πŸ‘οΈ0
ORCA ORCA 5 months ago
AS OF NOW PER SCHWAB IT IS VERY HARD TO FIND SHARES TO SHORT.WELL THAT IS GOING TO BE A B$TCH FOR SHORTS.
πŸ‘οΈ0
ORCA ORCA 5 months ago
ORCA IS LOOKING TO GET BACK IN AGAIN.THE PPS IS COMING DOWN TO MY ENTERING PRICES:)))
πŸ‘οΈ0
MightyX MightyX 5 months ago
This is their reload zone evidently..price going higher
πŸ‘οΈ0
MightyX MightyX 5 months ago
Under 15min remaining for them to fake-volume trade this..lol
πŸ‘οΈ0
MightyX MightyX 5 months ago
Price rising with volume
πŸ‘οΈ0
MightyX MightyX 5 months ago
Wonder which partner Tempest selects for its TPST treatment.
πŸ‘οΈ0
MightyX MightyX 6 months ago
β€œTempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)”
πŸ‘οΈ0
MightyX MightyX 6 months ago
20k share trade at $3.42
πŸ‘οΈ0
MightyX MightyX 6 months ago
Grabbed $3.50’s..should find out who they partnered with..soon enough
πŸ‘οΈ0
MightyX MightyX 6 months ago
Grabbed some $3.70’s for next run over $5
πŸ‘οΈ0
MightyX MightyX 6 months ago
Must be todays conference causing rally
πŸ‘οΈ0
MightyX MightyX 6 months ago
Up 13%
πŸ‘οΈ0
MightyX MightyX 6 months ago
Up 12% 2nd million..let’s see 3rd
πŸ‘οΈ0
tickersym tickersym 6 months ago
Very Nice !!
πŸ‘οΈ0
tickersym tickersym 6 months ago
Looks ready!!
πŸ‘οΈ0
MightyX MightyX 6 months ago
Up 7% 1st million volume..let’s see after 2nd
πŸ‘οΈ0
MightyX MightyX 6 months ago
Yall musta seen 911 trade..bout40min before $3.80’s breakout l..yesterday
πŸ‘οΈ0
MightyX MightyX 6 months ago
Yall arent very good@what yall do..still got all-my shares
πŸ‘οΈ0
MightyX MightyX 6 months ago
Yep
πŸ‘οΈ0
MightyX MightyX 6 months ago
Bulls taking control premarket evidently
πŸ‘οΈ0
MightyX MightyX 6 months ago
16,745 share trade at $3.83
πŸ‘οΈ0
MightyX MightyX 6 months ago
β€œTempest to Present at the 35th Annual Piper Sandler Healthcare Conference”
πŸ‘οΈ0
MightyX MightyX 6 months ago
News out or market just happy to see me?
πŸ‘οΈ0
tickersym tickersym 6 months ago
All Aboard!!!
πŸ‘οΈ0
bigfart bigfart 6 months ago
$5 would be nice
πŸ‘οΈ0
MightyX MightyX 6 months ago
$4’s and $5’s this week?
πŸ‘οΈ0
TheGreenReaper TheGreenReaper 6 months ago
TPST$$$$$
LETS GET IT.
πŸ‘οΈ0
tickersym tickersym 6 months ago
Looking great today!!!
πŸ‘οΈ0
MightyX MightyX 6 months ago
Y’all aren’t very good at what y’all do lol
πŸ‘οΈ0
MightyX MightyX 6 months ago
Y’all gave up too many shares…now I’ve got more.
πŸ‘οΈ0
MightyX MightyX 6 months ago
Inherent risk in industry..temporary
πŸ‘οΈ0
ORCA ORCA 6 months ago
THIS POS IS LOSING AN ENORMOUS AMOUNT OF MONEY.IT SHOULD BE TRADING IN THE .30 AREA.MAX.
Cash and cash equivalents at the end of the third quarter were $11.1 million, compared to $31.2 million on December 31, 2022.
β€’
Net loss and net loss per share for the quarter ended September 30, 2023 were $6.8 million and $0.48, respectively, compared to $8.9 million and $0.66, respectively, for the same period in 2022.
β€’
Research and development expenses for the quarter ended September 30, 2023 were $4.2 million compared to $6.0 million for the same period in 2022. The $1.8 million decrease was primarily due to a decrease in costs incurred from contract research organizations and third-party vendors.
β€’
General and administrative expenses for the quarter ended September 30, 2023 were $2.4 million compared to $2.8 million for the same period in 2022. The decrease was primarily due to a decrease in consulting and professional expenses and personnel costs.


Year-to-Date

β€’
Net cash used in operations for the nine months ended September 30, 2023 was $21.2 million.
β€’
Net loss and net loss per share for the nine months ended September 30, 2023 were $22.0 million and $1.57, respectively, compared to $26.6 million and $2.46, respectively, for the same period in 2022.
Research and development expenses for the nine months ended September 30, 2023 were $13.3 million compared to $16.7 million for the same period in 2022. The $3.4 million decrease was primarily due to a decrease in costs incurred from contract research organizations and third-party vendors, partially offset by an increase in facilities expenses.
β€’
General and administrative expenses for the nine months ended September 30, 2023 were $8.3 million compared to $9.0 million for the same period in 2022. The $0.7 million decrease was primarily due to a decrease in consulting and professional expenses.
πŸ‘οΈ0
MightyX MightyX 6 months ago
Nice premarket movement on earnings report..no chart signal lmao.
πŸ‘οΈ0
MightyX MightyX 6 months ago
β€œTempest Reports Third Quarter 2023 Financial Results and Provides Business Update”
πŸ‘οΈ0
bigboard bigboard 6 months ago
This is scam !! stay away, most phase 2 pumps are scams
They fail in phase 3
πŸ‘οΈ0
jdes jdes 6 months ago
Yeah but what a pump. From .17 to 9.77 in one day!!! Just had to be lucky that day.
πŸ‘οΈ0
TheGreenReaper TheGreenReaper 6 months ago
Nope, anytime before the 14th
πŸ‘οΈ0
bigboard bigboard 6 months ago
On the way to 0.75 !!! This was total pump n dump scam
πŸ‘οΈ0
MightyX MightyX 6 months ago
Earnings come out Tuesday?
πŸ‘οΈ0
TheGreenReaper TheGreenReaper 6 months ago
Waiting on the reversal signal.
πŸ‘οΈ0
MightyX MightyX 6 months ago
That’s just dumb say trader verbiage..no actual knives falling..lol
πŸ‘οΈ0